查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1666183

全球多平行生物反應器市場 - 2025 至 2033 年

Global Multi Parallel Bioreactors Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024 年全球多平行生物反應器市場規模達到 12.8 億美元，預計到 2033 年將達到 26.1 億美元，在 2025-2033 年預測期內的複合年成長率為 8.6%。

全球多平行生物反應器市場專注於先進的生物反應器系統，該系統可同時促進多個小規模實驗，從而增強生物過程最佳化。這些系統廣泛應用於製藥、生物技術、學術研究和生物基產業，可實現高效篩選、製程開發和擴大規模。多平行生物反應器具有即時監控、參數精確控制和高通量功能，在生物製藥、疫苗和生物燃料的生產中發揮著至關重要的作用。它們簡化和加速流程開發的能力使它們在現代生物製造中不可或缺。

在對生物製劑、生物相似藥和個人化醫療的需求不斷成長的推動下，市場正在經歷快速成長。隨著製藥和生物技術公司專注於開發針對特定患者的治療方法，多並行生物反應器對於最佳化生物過程至關重要。此外，人們對生物塑膠和生物燃料等永續生物基產品的日益重視，也推動了對這些先進生物反應器系統的需求。多並行生物反應器支援永續且經濟高效的生產的能力預計將推動市場進一步擴張。這些因素推動了全球多平行生物反應器市場的擴張。

市場動態：

促進因素與約束因素

生物製藥需求不斷成長

受生物製藥尤其是個人化醫療需求激增的推動，全球多平行生物反應器市場正在迅速擴張。這些生物反應器有助於最佳化複雜治療性蛋白質、單株抗體和疫苗的生產，這些對於滿足全球日益成長的醫療保健需求至關重要。多台並聯生物反應器可實現高精度控制，這對於維持生物製藥產品的品質和一致性至關重要。它們的多功能性受到需要靈活生物製造程序的行業的高度重視。

多並行生物反應器的主要使用者包括研究機構、合約研究組織（CRO）和合約製造組織（CMO），他們依靠這些系統進行製程開發和大規模生產。自動化、資料分析和一次性生物反應器系統的日益普及等技術進步，透過提高效率、降低污染風險和降低營運成本，進一步推動了市場成長。隨著生物製藥行業的不斷發展，多平行生物反應器在滿足該行業對更快、更永續生產日益成長的需求方面發揮著至關重要的作用。

此外，該行業的關鍵參與者推動了這一市場的成長。例如，2023 年 8 月，Sartorius 和 Repligen Corporation 推出了一款整合式生物反應器系統，該系統將 Sartorius 的 Biostat STR 攪拌釜反應器與 Repligen 的 XCell 交替切向流 (ATF) 上游強化技術結合。此新系統旨在簡化生物製藥製造商的強化種子培養和 N 灌注實施等流程。所有這些因素都要求全球多平行生物反應器市場。

此外，對生物製劑的需求不斷成長，促進了全球多平行生物反應器市場的擴張。

初期投資成本高

全球多平行生物反應器市場受到高初始投資成本的顯著影響，這對其廣泛採用構成了重大限制，特別是在較小的公司或研究機構中。包括自動化和複雜系統整合在內的先進技術推高了購買和維護這些生物反應器的成本。

這種財務障礙通常會限制它們的使用，只有較大的生物製藥公司或資金充足的研究機構才能使用。儘管在可擴展性和精確度方面具有優勢，但這些系統所需的前期資本可能會高得令人望而卻步。因此，上述因素可能會限制全球多平行生物反應器市場的潛在成長。

目錄

第 1 章：方法與範圍

第 2 章：定義與概述

第 3 章：執行摘要

第 4 章：動態

  • 影響因素
    • 驅動程式
      • 生物製藥需求不斷成長
    • 限制
      • 初期投資成本高
    • 機會
    • 影響分析

第5章：戰略洞察與產業展望

  • 市場領導者和先驅者
  • 新興先鋒和傑出參與者
  • 擁有最大、最暢銷品牌的成熟領導者
  • 擁有成熟產品的市場領導者
  • CXO 觀點
  • 最新進展與突破
  • 案例研究/正在進行的研究
  • 監管和報銷情況
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東和非洲
  • 波特五力分析
  • 供應鏈分析
  • 專利分析
  • SWOT 分析
  • 未滿足的需求和差距
  • 市場進入和擴張的推薦策略
  • 情境分析：最佳情況、基本情況和最壞情況預測
  • 定價分析和價格動態
  • 關鍵意見領袖

第 6 章：按類型

  • 4 生物反應器
  • 8 生物反應器
  • 16 生物反應器
  • 其他

第 7 章：按產品類型

  • 規模
    • 桌上型生物反應器（最大 15L）
    • 中試規模生物反應器（15-1000L）
    • 工業規模生物反應器（>1000L）
  • 材料
    • 玻璃生物反應器
    • 不銹鋼生物反應器
    • 免洗生物反應器

第 8 章：按生物反應器配置

  • 攪拌槽式生物反應器
  • 氣升式生物反應器

第 9 章：按情態

  • 手動的
  • 自動的
  • 半自動

第 10 章：按技術

  • 上游
  • 下游

第 11 章：按細胞

  • 哺乳動物細胞
  • 細菌細胞
  • 酵母菌細胞
  • 其他

第 12 章：按分子

  • 單株抗體
  • 疫苗
  • 重組蛋白
  • 幹細胞
  • 基因治療
  • 其他

第 13 章：按應用

  • 製藥業
  • 生物化工
  • 食品工業
  • 其他

第 14 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲

第 15 章：競爭格局

  • 競爭格局
  • 市場定位/佔有率分析
  • 併購分析

第 16 章：公司簡介

  • Sartorius AG
    • 公司概況
    • 產品組合
      • 產品描述
      • 產品關鍵績效指標 (KPI)
      • 歷史和預測產品銷售量
      • 產品銷售量
    • 財務概覽
      • 公司收入
      • 地區收入佔有率
      • 收入預測
    • 主要進展
      • 合併與收購
      • 關鍵產品開發活動
      • 監管部門批准等
    • SWOT 分析
  • Infors AG
  • HEL Group
  • Liaoyang Sinotech Technology Development Co., Ltd.
  • TJX Bioengineering
  • HiTec Zang GmbH
  • 2mag AG
  • KBiotech GmBH
  • Belach Bioteknik.
  • Corning Incorporated

第 17 章：附錄

簡介目錄
Product Code: PH9197

The global multi-parallel bioreactors market reached US$ 1.28 billion in 2024 and is expected to reach US$ 2.61 billion by 2033, growing at a CAGR of 8.6 % during the forecast period 2025-2033.

The global multi-parallel bioreactors market focuses on advanced bioreactor systems that facilitate multiple small-scale experiments simultaneously, enhancing bioprocess optimization. These systems are widely used in pharmaceuticals, biotechnology, academic research, and bio-based industries, allowing for efficient screening, process development, and scale-up. With real-time monitoring, precise control over parameters, and high-throughput capabilities, multi-parallel bioreactors play a vital role in the production of biopharmaceuticals, vaccines, and biofuels. Their ability to streamline and accelerate process development makes them indispensable in modern biomanufacturing.

The market is experiencing rapid growth, driven by the increasing demand for biologics, biosimilars, and personalized medicine. As pharmaceutical and biotech companies focus on developing patient-specific treatments, multi-parallel bioreactors have become essential for optimizing bioprocesses. Furthermore, the growing emphasis on sustainable bio-based products, such as bioplastics and biofuels, is fueling the demand for these advanced bioreactor systems. The ability of multi-parallel bioreactors to support sustainable and cost-effective production is expected to drive further market expansion. These factors have driven the global multi-parallel bioreactors market expansion.

Market Dynamics: Drivers & Restraints

Increasing Demand for Biopharmaceuticals

The global market for multi-parallel bioreactors is expanding rapidly, driven by the surging demand for biopharmaceuticals, especially personalized medicine. These bioreactors are instrumental in optimizing the production of complex therapeutic proteins, monoclonal antibodies, and vaccines, all of which are essential to meet the growing healthcare needs worldwide. Multi-parallel bioreactors enable high-precision control, which is crucial for maintaining the quality and consistency of biopharmaceutical products. Their versatility is highly valued across industries that require flexible biomanufacturing processes.

Key users of multi-parallel bioreactors include research institutions, contract research organizations (CROs), and contract manufacturing organizations (CMOs), which rely on these systems for both process development and large-scale production. Technological advancements, such as automation, data analytics, and the growing adoption of single-use bioreactor systems, are further propelling market growth by improving efficiency, reducing contamination risks, and lowering operational costs. As the biopharmaceutical industry continues to evolve, multi-parallel bioreactors play a vital role in meeting the sector's increasing demands for faster and more sustainable production.

Furthermore, key players in the industry launch drive this market growth. For instance, in August 2023, Sartorius and Repligen Corporation launched an integrated bioreactor system that combines Sartorius' Biostat STR stirred-tank reactor with Repligen's XCell Alternating Tangential Flow (ATF) upstream intensification technology. This new system is designed to simplify processes such as intensified seed train and N perfusion implementation for biopharmaceutical manufacturers. All these factors demand the global multi-parallel bioreactors market.

Moreover, the rising demand for biologics contributes to the global multi-parallel bioreactors market expansion.

High Initial Investment Costs

The global multi-parallel bioreactors market is significantly influenced by high initial investment costs, which pose a major restraint for widespread adoption, particularly among smaller companies or research institutions. The advanced technology, including automation and integration of complex systems, drives up the cost of purchasing and maintaining these bioreactors.

This financial barrier often limits their usage to larger biopharmaceutical companies or well-funded research organizations. Despite the advantages in scalability and precision, the upfront capital required for these systems can be prohibitive. Thus, the above factors could be limiting the global multi-parallel bioreactors market's potential growth.

Segment Analysis

The global multi-parallel bioreactors market is segmented based on type, product type, bioreactor configuration, modality, technology, cell, molecule, application, and region.

Type:

The 8 bioreactors segment is expected to dominate the global multi-parallel bioreactors market share

The 8 bioreactors segment holds a major portion of the global multi-parallel bioreactors market share and is expected to continue to hold a significant portion of the global multi-parallel bioreactors market share during the forecast period.

The 8 bioreactor systems are engineered to support high-throughput experimentation by allowing simultaneous testing of multiple conditions. This capability is essential for applications that demand efficiency, such as optimizing bioprocess parameters like temperature, pH, and nutrient concentrations across eight individual bioreactors. The configuration accelerates bioprocess development, enabling researchers to quickly identify optimal conditions for various cell cultures. These systems are particularly valuable in drug development, where time is critical and fast iteration of experiments is necessary.

One of the key advantages of 8 bioreactor systems is their scalability. They can be adapted for both small-scale experiments and larger production runs, making them highly versatile tools for research and development. Additionally, their high throughput significantly boosts research efficiency by enabling multiple experiments to run simultaneously. This feature not only saves time but also reduces costs associated with materials and operations when compared to larger single-use bioreactors. Moreover, the flexibility of these systems allows them to accommodate different cell cultures, including both mammalian and microbial cells, expanding their use across a range of biotechnology fields.

The growing demand for biopharmaceuticals, particularly biologics like monoclonal antibodies and vaccines, is a major driver for the increased use of 8 bioreactor systems. Technological advancements in bioprocessing further enhance the performance and reliability of these systems, making them indispensable in modern biotechnology. The shift towards personalized medicine also calls for adaptable and efficient production systems, which are a defining characteristic of 8 bioreactor configurations. Leading market players such as Sartorius AG and Thermo Fisher Scientific are focusing on improving these systems through innovation and advanced analytics to provide better process control. These factors have solidified the segment's position in the global multi-parallel bioreactors market.

Geographical Analysis

North America is expected to hold a significant position in the global multi-parallel bioreactors market share

North America holds a substantial position in the global multi-parallel bioreactors market and is expected to hold most of the market share, driven by several key factors. One of the primary drivers is the region's strong and well-established biopharmaceutical industry. The U.S. is a global leader in biotechnology and pharmaceutical development, with a high concentration of biopharmaceutical companies, research institutions, and government funding supporting life sciences research.

The increasing demand for biologics, such as monoclonal antibodies and vaccines, is fueling the need for advanced bioprocessing tools like multi-parallel bioreactors. These systems enable high-throughput experimentation and efficient process development, making them indispensable in meeting the growing demand for complex biological therapies.

In addition to the thriving biopharmaceutical sector, technological advancements are also driving the market. The integration of automation, data analytics, and artificial intelligence into bioreactors enhances process efficiency, scalability, and precision, making multi-parallel systems more attractive to companies involved in drug development.

Moreover, the shift toward personalized medicine, which demands flexible and adaptive production systems, further accelerates the adoption of multi-parallel bioreactors. As North American companies continue to invest in innovation and expand their biomanufacturing capabilities, the demand for these systems is expected to continue rising, positioning the region as a dominant player in the global multi-parallel bioreactors market.

Additionally, key players' strategies such as partnerships and collaborations would drive this global multi-parallel bioreactor market growth. For instance, in the U.S., in December 2024, Getinge and 908 Devices partnered to enhance bioreactor monitoring by integrating 908 Devices' MAVEN system with Getinge's bioreactors. This collaboration aims to provide real-time, continuous monitoring of key cell culture parameters, specifically glucose and lactate levels, without the need for manual sampling. Thus, the above factors are consolidating the region's position as a dominant force in the global multi-parallel bioreactors market.

Asia Pacific is growing at the fastest pace in the global multi-parallel bioreactors market share

Asia Pacific holds the fastest pace in the global multi-parallel bioreactors market and is expected to hold most of the market share driven by a combination of factors related to the region's expanding biotechnology and pharmaceutical industries. One of the main drivers is the increasing demand for biopharmaceutical products, especially in countries like China and India, where the biopharmaceutical sector is undergoing significant growth. These nations are investing heavily in biotechnology infrastructure, research and development, and the production of biologics, which has led to a rising need for advanced bioreactor systems like multi-parallel bioreactors.

These systems are essential for accelerating bioprocess development, and optimizing conditions for the production of complex drugs such as monoclonal antibodies and vaccines. Technological advancements in bioprocessing have made multi-parallel bioreactors more attractive to companies in the region. The adoption of automation, data analytics, and single-use technologies has enhanced the efficiency, scalability, and flexibility of bioreactor systems. These innovations are particularly important in addressing the challenges of producing biologics at scale and in a cost-effective manner. With Asia-Pacific's growing emphasis on personalized medicine and the increasing focus on rapid drug development, multi-parallel bioreactors are becoming key tools to meet these evolving demands.

Additionally, key players in the industry launch that would drive these global multi-parallel bioreactors market growth. For instance, in September 2024, VFL Sciences Private Limited introduced the GreatFlo series of benchtop fermenters/bioreactors, including the GreatFlo Expert and GreatFlo Proficient models. These systems are designed for versatility and come in capacities of up to 10 liters, with both autoclavable and in-situ sterilizable versions. They serve as advanced alternatives to existing models, offering cutting-edge features for fermentation and bioprocessing applications. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global multi-parallel bioreactors market.

Competitive Landscape

The major global players in the multi-parallel bioreactors market include Sartorius AG, Infors AG, H.E.L Group, Liaoyang Sinotech Technology Development Co., Ltd., TJX Bioengineering, HiTec Zang GmbH, 2mag AG, KBiotech GmBH, Belach Bioteknik., and Corning Incorporated among others.

Key Developments

  • In December 2024, METHER launched a new product in Shanghai called the Respiratory Bioreactor. While specific details about the bioreactor's capabilities were not provided in the available sources, it is likely a specialized device designed for biomedical and laboratory applications.
  • In March 2024, CytoNiche launched the 3D FloTrix vivaROCK Bioreactor System, a single-use rocking bioreactor designed for high-quality, large-scale 3D cell culture. This system is particularly suited for applications in scientific research, process development, and manufacturing.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global multi-parallel bioreactors market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Product Type
  • 3.3. Snippet by Bioreactor Configuration
  • 3.4. Snippet by Modality
  • 3.5. Snippet by Technology
  • 3.6. Snippet by Cell
  • 3.7. Snippet by Molecule
  • 3.8. Snippet by Application
  • 3.9. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Demand for Biopharmaceuticals
    • 4.1.2. Restraints
      • 4.1.2.1. High Initial Investment Costs
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
  • 5.2. Emerging Pioneers and Prominent Players
  • 5.3. Established leaders with largest largest-selling Brand
  • 5.4. Market leaders with established Product
  • 5.5. CXO Perspectives
  • 5.6. Latest Developments and Breakthroughs
  • 5.7. Case Studies/Ongoing Research
  • 5.8. Regulatory and Reimbursement Landscape
  • 5.9. North America
  • 5.10. Europe
  • 5.11. Asia Pacific
  • 5.12. Latin America
  • 5.13. Middle East & Africa
  • 5.14. Porter's Five Force Analysis
  • 5.15. Supply Chain Analysis
  • 5.16. Patent Analysis
  • 5.17. SWOT Analysis
  • 5.18. Unmet Needs and Gaps
  • 5.19. Recommended Strategies for Market Entry and Expansion
  • 5.20. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.21. Pricing Analysis and Price Dynamics
  • 5.22. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. 4 Bioreactors*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. 8 Bioreactors
  • 6.4. 16 Bioreactors
  • 6.5. Others

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Scale*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. Benchtop Bioreactors (Up to 15L)
    • 7.2.4. Pilot Scale Bioreactors (15-1000L)
    • 7.2.5. Industrial Scale Bioreactors (>1000L)
  • 7.3. Material
    • 7.3.1. Glass Bioreactors
    • 7.3.2. Stainless Steel Bioreactors
    • 7.3.3. Single-Use Bioreactors

8. By Bioreactor Configuration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 8.1.2. Market Attractiveness Index, By Bioreactor Configuration
  • 8.2. Stirred-Tank Bioreactors*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Airlift Bioreactors

9. By Modality

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 9.1.2. Market Attractiveness Index, By Modality
  • 9.2. Manual*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Automatic
  • 9.4. Semi-Automatic

10. By Technology

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  • 10.2. Market Attractiveness Index, By Technology
  • 10.3. Upstream*
    • 10.3.1. Introduction
    • 10.3.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.4. Downstream

11. By Cell

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 11.1.2. Market Attractiveness Index, By Cell
  • 11.2. Mammalian Cells*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Bacterial Cells
  • 11.4. Yeast Cells
  • 11.5. Others

12. By Molecule

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 12.1.2. Market Attractiveness Index, By Molecule
  • 12.2. Monoclonal Antibodies*
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Vaccines
  • 12.4. Recombinant Proteins
  • 12.5. Stem Cells
  • 12.6. Gene Therapy
  • 12.7. Others

13. By Application

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 13.1.2. Market Attractiveness Index, By Application
  • 13.2. Pharmaceutical Industry*
    • 13.2.1. Introduction
    • 13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 13.3. Biochemical Engineering
  • 13.4. Food Industry
  • 13.5. Others

14. By Region

  • 14.1. Introduction
    • 14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 14.1.2. Market Attractiveness Index, By Region
  • 14.2. North America
    • 14.2.1. Introduction
    • 14.2.2. Key Region-Specific Dynamics
    • 14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.2.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.2.11.1. U.S.
      • 14.2.11.2. Canada
      • 14.2.11.3. Mexico
  • 14.3. Europe
    • 14.3.1. Introduction
    • 14.3.2. Key Region-Specific Dynamics
    • 14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.3.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.3.11.1. Germany
      • 14.3.11.2. U.K.
      • 14.3.11.3. France
      • 14.3.11.4. Spain
      • 14.3.11.5. Italy
      • 14.3.11.6. Rest of Europe
  • 14.4. South America
    • 14.4.1. Introduction
    • 14.4.2. Key Region-Specific Dynamics
    • 14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.4.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.4.11.1. Brazil
      • 14.4.11.2. Argentina
      • 14.4.11.3. Rest of South America
  • 14.5. Asia-Pacific
    • 14.5.1. Introduction
    • 14.5.2. Key Region-Specific Dynamics
    • 14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 14.5.11. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 14.5.11.1. China
      • 14.5.11.2. India
      • 14.5.11.3. Japan
      • 14.5.11.4. South Korea
      • 14.5.11.5. Rest of Asia-Pacific
  • 14.6. Middle East and Africa
    • 14.6.1. Introduction
    • 14.6.2. Key Region-Specific Dynamics
    • 14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Bioreactor Configuration
    • 14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Modality
    • 14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell
    • 14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Molecule
    • 14.6.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

15. Competitive Landscape

  • 15.1. Competitive Scenario
  • 15.2. Market Positioning/Share Analysis
  • 15.3. Mergers and Acquisitions Analysis

16. Company Profiles

  • 16.1. Sartorius AG*
    • 16.1.1. Company Overview
    • 16.1.2. Product Portfolio
      • 16.1.2.1. Product Description
      • 16.1.2.2. Product Key Performance Indicators (KPIs)
      • 16.1.2.3. Historic and Forecasted Product Sales
      • 16.1.2.4. Product Sales Volume
    • 16.1.3. Financial Overview
      • 16.1.3.1. Company Revenue's
      • 16.1.3.2. Geographical Revenue Shares
      • 16.1.3.3. Revenue Forecasts
    • 16.1.4. Key Developments
      • 16.1.4.1. Mergers & Acquisitions
      • 16.1.4.2. Key Product Development Activities
      • 16.1.4.3. Regulatory Approvals etc.
    • 16.1.5. SWOT Analysis
  • 16.2. Infors AG
  • 16.3. H.E.L Group
  • 16.4. Liaoyang Sinotech Technology Development Co., Ltd.
  • 16.5. TJX Bioengineering
  • 16.6. HiTec Zang GmbH
  • 16.7. 2mag AG
  • 16.8. KBiotech GmBH
  • 16.9. Belach Bioteknik.
  • 16.10. Corning Incorporated

LIST NOT EXHAUSTIVE

17. Appendix

  • 17.1. About Us and Services
  • 17.2. Contact Us